OBJECTIVE: To examine associations between labial salivary gland (LSG) histopathology and other phenotypic features of Sjögren's syndrome (SS). METHODS: The database of the Sjögren's International Collaborative Clinical Alliance (SICCA), a registry of patients with symptoms of possible SS as well as those with obvious disease, was used for the present study. LSG biopsy specimens from SICCA participants were subjected to protocol-directed histopathologic assessments. Among the 1,726 LSG specimens exhibiting any pattern of sialadenitis, we compared biopsy diagnoses against concurrent salivary, ocular, and serologic features. RESULTS: LSG specimens included 61% with focal lymphocytic sialadenitis (FLS; 69% of which had focus scores of ≥1 per 4 mm²) and 37% with nonspecific or sclerosing chronic sialadenitis (NS/SCS). Focus scores of ≥1 were strongly associated with serum anti-SSA/SSB positivity, rheumatoid factor, and the ocular component of SS, but not with symptoms of dry mouth or dry eyes. Those with positive anti-SSA/SSB were 9 times (95% confidence interval [95% CI] 7.4-11.9) more likely to have a focus score of ≥1 than were those without anti-SSA/SSB, and those with an unstimulated whole salivary flow rate of <0.1 ml/minute were 2 times (95% CI 1.7-2.8) more likely to have a focus score of ≥1 than were those with a higher flow rate, after controlling for other phenotypic features of SS. CONCLUSION: Distinguishing FLS from NS/SCS is essential in assessing LSG biopsies, before determining focus score. A diagnosis of FLS with a focus score of ≥1 per 4 mm², as compared to FLS with a focus score of <1 or NS/SCS, is strongly associated with the ocular and serologic components of SS and reflects SS autoimmunity.
OBJECTIVE: To examine associations between labial salivary gland (LSG) histopathology and other phenotypic features of Sjögren's syndrome (SS). METHODS: The database of the Sjögren's International Collaborative Clinical Alliance (SICCA), a registry of patients with symptoms of possible SS as well as those with obvious disease, was used for the present study. LSG biopsy specimens from SICCAparticipants were subjected to protocol-directed histopathologic assessments. Among the 1,726 LSG specimens exhibiting any pattern of sialadenitis, we compared biopsy diagnoses against concurrent salivary, ocular, and serologic features. RESULTS: LSG specimens included 61% with focal lymphocytic sialadenitis (FLS; 69% of which had focus scores of ≥1 per 4 mm²) and 37% with nonspecific or sclerosing chronic sialadenitis (NS/SCS). Focus scores of ≥1 were strongly associated with serum anti-SSA/SSB positivity, rheumatoid factor, and the ocular component of SS, but not with symptoms of dry mouth or dry eyes. Those with positive anti-SSA/SSB were 9 times (95% confidence interval [95% CI] 7.4-11.9) more likely to have a focus score of ≥1 than were those without anti-SSA/SSB, and those with an unstimulated whole salivary flow rate of <0.1 ml/minute were 2 times (95% CI 1.7-2.8) more likely to have a focus score of ≥1 than were those with a higher flow rate, after controlling for other phenotypic features of SS. CONCLUSION: Distinguishing FLS from NS/SCS is essential in assessing LSG biopsies, before determining focus score. A diagnosis of FLS with a focus score of ≥1 per 4 mm², as compared to FLS with a focus score of <1 or NS/SCS, is strongly associated with the ocular and serologic components of SS and reflects SS autoimmunity.
Authors: C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman Journal: Ann Rheum Dis Date: 2002-06 Impact factor: 19.103
Authors: Stina Salomonsson; Malin V Jonsson; Kathrine Skarstein; Karl A Brokstad; Peter Hjelmström; Marie Wahren-Herlenius; Roland Jonsson Journal: Arthritis Rheum Date: 2003-11
Authors: John P Whitcher; Caroline H Shiboski; Stephen C Shiboski; Ana Maria Heidenreich; Kazuko Kitagawa; Shunhua Zhang; Steffen Hamann; Genevieve Larkin; Nancy A McNamara; John S Greenspan; Troy E Daniels Journal: Am J Ophthalmol Date: 2009-12-29 Impact factor: 5.258
Authors: S C Shiboski; C H Shiboski; L A Criswell; A N Baer; S Challacombe; H Lanfranchi; M Schiødt; H Umehara; F Vivino; Y Zhao; Y Dong; D Greenspan; A M Heidenreich; P Helin; B Kirkham; K Kitagawa; G Larkin; M Li; T Lietman; J Lindegaard; N McNamara; K Sack; P Shirlaw; S Sugai; C Vollenweider; J Whitcher; A Wu; S Zhang; W Zhang; J S Greenspan; T E Daniels Journal: Arthritis Care Res (Hoboken) Date: 2012-04 Impact factor: 4.794
Authors: Michelle L Joachims; Kerry M Leehan; Christina Lawrence; Richard C Pelikan; Jacen S Moore; Zijian Pan; Astrid Rasmussen; Lida Radfar; David M Lewis; Kiely M Grundahl; Jennifer A Kelly; Graham B Wiley; Mikhail Shugay; Dmitriy M Chudakov; Christopher J Lessard; Donald U Stone; R Hal Scofield; Courtney G Montgomery; Kathy L Sivils; Linda F Thompson; A Darise Farris Journal: JCI Insight Date: 2016-06-02
Authors: Barbara M Szczerba; Paulina Kaplonek; Nina Wolska; Anna Podsiadlowska; Paulina D Rybakowska; Paromita Dey; Astrid Rasmussen; Kiely Grundahl; Kimberly S Hefner; Donald U Stone; Stephen Young; David M Lewis; Lida Radfar; R Hal Scofield; Kathy L Sivils; Harini Bagavant; Umesh S Deshmukh Journal: Ann Rheum Dis Date: 2015-02-05 Impact factor: 19.103
Authors: Jill M Kramer; Nichol E Holodick; Teresa C Vizconde; Indu Raman; Mei Yan; Quan-Zhen Li; Daniel P Gaile; Thomas L Rothstein Journal: J Leukoc Biol Date: 2015-09-17 Impact factor: 4.962
Authors: Caroline H Shiboski; Alan N Baer; Stephen C Shiboski; Mi Lam; Stephen Challacombe; Hector E Lanfranchi; Morten Schiødt; Penelope Shirlaw; Muthiah Srinivasan; Hisanori Umehara; Frederick B Vivino; Esen Akpek; Vatinee Bunya; Cristina F Vollenweider; John S Greenspan; Troy E Daniels; Lindsey A Criswell Journal: Arthritis Care Res (Hoboken) Date: 2018-01-03 Impact factor: 4.794